We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31 | -0.86% | 35.71 | 35.27 | 36.58 | 36.0612 | 35.63 | 36.01 | 23,462 | 21:30:16 |
From Sep 2022 to Sep 2024
By Cecilia Butini
Merck KGaA's French subsidiary was indicted by a judge in the French city of Marseille after complaints were filed against a change in formulation of a thyroid drug it produces.
The German pharmaceutical and technology company said that the investigation is about the information received by patients on the formulation change of the drug, which is named Levothyrox. It is "not linked to the quality of the new formulation," it said.
The change was prompted by a 2012 request from French authorities, which required companies making thyroid treatments to tighten specifications for levothyroxine sodium content in order to improve the stability of the drug, according to Merck. The new formulation is approved in more than 40 countries, it said.
The company said it is cooperating fully with the justice system.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 19, 2022 09:43 ET (13:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
